Morning Market Movers
January 07, 2014 at 10:07 AM EST
Neurocrine Biosciences (NASDAQ: NBIX ) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. Epizyme (NASDAQ: EPZM ) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept
